Global Anti-nuclear Antibody Testing Market - Drivers and Forecasts by Technavio

Technavio has published a new report on the global anti-nuclear antibody (ANA) testing market from 2017-2021. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global anti-nuclear antibody (ANA) testing market to grow at a CAGR of more than 7% during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global ANA testing market for 2017-2021. The market is segmented based on end-user (hospitals and clinical diagnostics laboratories), and geography (the Americas, EMEA, and APAC).

The global ANA testing market will grow at a rapid pace during the forecast period due to the rise in the incidence of autoimmune diseases worldwide. The sales of autoimmune disease diagnostics, particularly immunodiagnostic products, were high in Japan and countries in North America and Western Europe. Medical facilities in these countries have improved, resulting in laboratory automation and adoption of advanced products for quality treatment. The emerging countries in Central and South America and Central Europe, along with Brazil, Russia, India, and China (BRIC) present significant opportunities for vendors to grow.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio healthcare and life sciences research analysts highlight the following three factors that are contributing to the growth of the global ANA testing market:

  • Increased prevalence of autoimmune diseases
  • Discovery of novel biomarkers
  • Advances in laboratory automation platforms

Increased prevalence of autoimmune diseases

Autoimmune diseases can affect any organ or system in the body, with the symptoms varying among disease types. There are about 80 types of autoimmune diseases in the world. Rheumatoid arthritis, Lupus, Celiac disease, and multiple sclerosis are some of the autoimmune diseases.

Srinivas Sashidhar, a lead in-vitro diagnostics research analyst at Technavio, says, “Type 1 diabetes is a localized autoimmune disease. The growing incidence of type 1 diabetes is expected to drive the market growth. The growing demand for POC testing for diabetes management is expected to change the market dynamics, owing to its ability to diagnose quickly.

Discovery of novel biomarkers

The development of novel biomarkers has resulted in improved diagnosis of autoimmune diseases. There is an increased demand for multiple biomarkers to identify and evaluate patient status, disease type, progression, and response to therapy for autoimmune diseases.

The development of auto-antibodies in a given protein is witnessed only in a limited number of individuals affected with the disease. Thus, vendors and research institutes are conducting exhaustive R&D activities and posting promising results in the use of multiple biomarkers for the diagnosis of autoimmune diseases,” adds Srinivas.

Advances in laboratory automation platforms

The incidence of autoimmune diseases is rising worldwide, which is increasing the volume of samples being collected for analysis. This has led to the demand for automation in autoimmune disease diagnostics for rapid analysis and interpretation of results. Automation involves a series of integrated steps that include pre-analytical and post-analytical stages to help minimize the need for manual intervention, thus avoiding errors.

Vendors like Abbott Laboratories, Beckman Coulter, Siemens Healthcare, and Inova Diagnostics are offering automated systems to central and medium-sized laboratories for sample analysis. Some of these systems are available as standalone or integrated analyzers, which can assess various assays apart from autoimmune diagnostic assays.

Top vendors:

  • Abbott Laboratories
  • Alere
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, life science research tools, and cardiovascular and metabolic disorders. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770

Release Summary

Technavio analysts forecast the global anti-nuclear antibody (ANA) testing market to grow at a CAGR of more than 7% during the forecast period, according to their latest report.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770